Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 18;10(4):1367-1401.
doi: 10.1016/j.gendis.2022.02.007. eCollection 2023 Jul.

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

Uttpal Anand  1 , Abhijit Dey  2 , Arvind K Singh Chandel  3 , Rupa Sanyal  4 , Amarnath Mishra  5 , Devendra Kumar Pandey  6 , Valentina De Falco  7 , Arun Upadhyay  8 , Ramesh Kandimalla  9   10 , Anupama Chaudhary  11 , Jaspreet Kaur Dhanjal  12 , Saikat Dewanjee  13 , Jayalakshmi Vallamkondu  14 , José M Pérez de la Lastra  15
Affiliations
Review

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

Uttpal Anand et al. Genes Dis. .

Erratum in

Abstract

Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and produce aggressive malignancies that causes millions of deaths every year. With the new understanding of the molecular mechanism(s) of disease progression, our knowledge about the disease is snowballing, leading to the evolution of many new therapeutic regimes and their successive trials. In the past few decades, various combinations of therapies have been proposed and are presently employed in the treatment of diverse cancers. Targeted drug therapy, immunotherapy, and personalized medicines are now largely being employed, which were not common a few years back. The field of cancer discoveries and therapeutics are evolving fast as cancer type-specific biomarkers are progressively being identified and several types of cancers are nowadays undergoing systematic therapies, extending patients' disease-free survival thereafter. Although growing evidence shows that a systematic and targeted approach could be the future of cancer medicine, chemotherapy remains a largely opted therapeutic option despite its known side effects on the patient's physical and psychological health. Chemotherapeutic agents/pharmaceuticals served a great purpose over the past few decades and have remained the frontline choice for advanced-stage malignancies where surgery and/or radiation therapy cannot be prescribed due to specific reasons. The present report succinctly reviews the existing and contemporary advancements in chemotherapy and assesses the status of the enrolled drugs/pharmaceuticals; it also comprehensively discusses the emerging role of specific/targeted therapeutic strategies that are presently being employed to achieve better clinical success/survival rate in cancer patients.

Keywords: Antimicrobial peptides; Cancer therapies; Clinical trials; Combination therapy; Immunotherapy; Patient survival; Personalized medicine; Targeted drug delivery.

PubMed Disclaimer

Figures

Fig. 1
Figure 1
Schematic diagram showing different intrinsic and extrinsic biological/molecular events potentiating the transformation of a normal cell to the cancer cell, while the lower part of this diagram showing different hallmarks of a transformed cancer cell.
Fig. 2
Figure 2
Schematic diagram showing the basic principles of chemotherapy (A), different classes of chemotherapeutic agents/drugs (B), and immunotherapeutic mechanism(s) of targeting cancer cells (C).
Fig. 3
Figure 3
Schematic diagram showing targeted cancer therapeutic approaches. (A) Model showing targeted drug delivery approach of anti-cancer drugs/chemical agents conjugated with receptor substrate specific to the cancer cell receptor. (B) Model showing the building of a personalized medicine approach based on omics data and drug response study targeting specific mutation/signature in individual patients for precision cancer therapeutics. (C) Model showing immunotherapeutic regime involving reprogramming of T-cells to target cancer cells by a chimeric antigen receptor for their application in cancer immunotherapy.
Fig. 4
Figure 4
Advantages of antimicrobial peptides as anti-tumor agents.
See this image and copyright information in PMC

Similar articles

  • Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E, Fernández-Medarde A. Pérez-Herrero E, et al. Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Eur J Pharm Biopharm. 2015. PMID: 25813885 Review.
  • Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Ascierto PA, et al. J Transl Med. 2016 Nov 15;14(1):313. doi: 10.1186/s12967-016-1070-y. J Transl Med. 2016. PMID: 27846884 Free PMC article.
  • Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Pasquali S, et al. Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article. Review.
  • [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
  • Palliative Treatment of Cancer-Related Pain [Internet].
    Kongsgaard U, Kaasa S, Dale O, Ottesen S, Nordøy T, Hessling SE, von Hofacker S, Bruland ØS, Lyngstadaas A. Kongsgaard U, et al. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005 Dec. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 09-2005. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005 Dec. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 09-2005. PMID: 29320015 Free Books & Documents. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Janssen L.M.E., Ramsay E.E., Logsdon C.D., Overwijk W.W. The immune system in cancer metastasis: friend or foe? J Immunother Cancer. 2017;5(1):79. - PMC - PubMed
    1. Laplagne C., Domagala M., le Naour A., et al. Latest advances in targeting the tumor microenvironment for tumor suppression. Int J Mol Sci. 2019;20(19):4719. - PMC - PubMed
    1. Emon B., Bauer J., Jain Y., Jung B., Saif T. Biophysics of tumor microenvironment and cancer metastasis - a mini review. Comput Struct Biotechnol J. 2018;16:279–287. - PMC - PubMed
    1. Costa A., Scholer-Dahirel A., Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin Cancer Biol. 2014;25:23–32. - PubMed
    1. Gilbert S., Oliphant C., Hassan S., et al. ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival. Oncogene. 2019;38(2):194–208. - PMC - PubMed

LinkOut - more resources